Editorial
Postoperative capecitabine in breast cancer neoadjuvant failures
Abstract
In the 1 June 2017 issue of New England Journal of Medicine, Masuda et al. presented important new findings on capecitabine in HER2-negative breast cancer (1). All patients received standard neoadjuvant chemotherapy treatment before surgery with an anthracycline or a taxane, or both. Masuda et al. gave oral capecitabine, 1,250 mg/m2
twice daily on days 1 to 14, nothing days 15 to 21, for 6 to 8 cycles after surgical resection to those whose surgical tissue showed residual invasive breast cancer.
twice daily on days 1 to 14, nothing days 15 to 21, for 6 to 8 cycles after surgical resection to those whose surgical tissue showed residual invasive breast cancer.
